News | November 14, 2025
Hormone therapy for menopause gets green light from FDA
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
FIBROSARC did not meet its primary PFS endpoint in the final analysi
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
